Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience
Abstract Background This case study describes how a public-private partnership initiated to develop a new anti-malarial combination, ASAQ Winthrop, has evolved over time to address issues posed by its effective deployment in the field. Case description In 2002, DND i created the FACT project to deve...
Published in: | Malaria Journal |
---|---|
Main Authors: | , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMC
2011
|
Subjects: | |
Online Access: | https://doi.org/10.1186/1475-2875-10-143 https://doaj.org/article/8a22bf2c781c46a7b5649a589de37dad |
id |
ftdoajarticles:oai:doaj.org/article:8a22bf2c781c46a7b5649a589de37dad |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:8a22bf2c781c46a7b5649a589de37dad 2023-05-15T15:17:58+02:00 Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience Sebbag Robert Kiechel Jean-René Bompart François Pecoul Bernard 2011-05-01T00:00:00Z https://doi.org/10.1186/1475-2875-10-143 https://doaj.org/article/8a22bf2c781c46a7b5649a589de37dad EN eng BMC http://www.malariajournal.com/content/10/1/143 https://doaj.org/toc/1475-2875 doi:10.1186/1475-2875-10-143 1475-2875 https://doaj.org/article/8a22bf2c781c46a7b5649a589de37dad Malaria Journal, Vol 10, Iss 1, p 143 (2011) Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 article 2011 ftdoajarticles https://doi.org/10.1186/1475-2875-10-143 2022-12-30T21:42:01Z Abstract Background This case study describes how a public-private partnership initiated to develop a new anti-malarial combination, ASAQ Winthrop, has evolved over time to address issues posed by its effective deployment in the field. Case description In 2002, DND i created the FACT project to develop two fixed-dose combinations, artesunate-amodiaquine and artesunate-mefloquine, to meet the WHO anti-malarial treatment recommendations and international regulatory agencies approval standards. In 2002, Sanofi-aventis had started a development programme for a fixed-dose combination of artesunate and amodiaquine, to replace its co-blister combination. DND i and sanofi-aventis joined forces in 2004, with the objective of developing within the shortest possible time frame a non-patented, affordable and easy to use fixed-dose combination of artesunate and amodiaquine adapted to the needs of patients, in particular, those of children. The partners developed Coarsucam ® /Artesunate Amodiaquine Winthrop ® ("ASAQ Winthrop") which was prequalified by the WHO in 2008. Additional partnerships have since been established by DND i and sanofi-aventis to ensure: 1) the adoption of this new medicine by malaria-endemic countries, 2) its appropriate usage through a broad range of information tools, and 3) the monitoring of its safety and efficacy in the field through an innovative Risk Management Plan. Discussion and evaluation The partnership between DND i and sanofi-aventis has enabled the development and pre-qualification of ASAQ Winthrop in a short timeframe. As a result of the multiple collaborations established by the two partners, as of late 2010, ASAQ Winthrop was registered in 30 sub-Saharan African countries and in India, with over 80 million treatments distributed in 21 countries. To date, 10 clinical studies, involving 3432 patients with ASAQ Winthrop were completed to document efficacy and safety issues identified in the Risk Management Plan. Conclusions The speed at which ASAQ Winthrop was adopted in the field shows ... Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Malaria Journal 10 1 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
spellingShingle |
Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 Sebbag Robert Kiechel Jean-René Bompart François Pecoul Bernard Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience |
topic_facet |
Arctic medicine. Tropical medicine RC955-962 Infectious and parasitic diseases RC109-216 |
description |
Abstract Background This case study describes how a public-private partnership initiated to develop a new anti-malarial combination, ASAQ Winthrop, has evolved over time to address issues posed by its effective deployment in the field. Case description In 2002, DND i created the FACT project to develop two fixed-dose combinations, artesunate-amodiaquine and artesunate-mefloquine, to meet the WHO anti-malarial treatment recommendations and international regulatory agencies approval standards. In 2002, Sanofi-aventis had started a development programme for a fixed-dose combination of artesunate and amodiaquine, to replace its co-blister combination. DND i and sanofi-aventis joined forces in 2004, with the objective of developing within the shortest possible time frame a non-patented, affordable and easy to use fixed-dose combination of artesunate and amodiaquine adapted to the needs of patients, in particular, those of children. The partners developed Coarsucam ® /Artesunate Amodiaquine Winthrop ® ("ASAQ Winthrop") which was prequalified by the WHO in 2008. Additional partnerships have since been established by DND i and sanofi-aventis to ensure: 1) the adoption of this new medicine by malaria-endemic countries, 2) its appropriate usage through a broad range of information tools, and 3) the monitoring of its safety and efficacy in the field through an innovative Risk Management Plan. Discussion and evaluation The partnership between DND i and sanofi-aventis has enabled the development and pre-qualification of ASAQ Winthrop in a short timeframe. As a result of the multiple collaborations established by the two partners, as of late 2010, ASAQ Winthrop was registered in 30 sub-Saharan African countries and in India, with over 80 million treatments distributed in 21 countries. To date, 10 clinical studies, involving 3432 patients with ASAQ Winthrop were completed to document efficacy and safety issues identified in the Risk Management Plan. Conclusions The speed at which ASAQ Winthrop was adopted in the field shows ... |
format |
Article in Journal/Newspaper |
author |
Sebbag Robert Kiechel Jean-René Bompart François Pecoul Bernard |
author_facet |
Sebbag Robert Kiechel Jean-René Bompart François Pecoul Bernard |
author_sort |
Sebbag Robert |
title |
Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience |
title_short |
Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience |
title_full |
Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience |
title_fullStr |
Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience |
title_full_unstemmed |
Innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the ASAQ Winthrop experience |
title_sort |
innovative public-private partnerships to maximize the delivery of anti-malarial medicines: lessons learned from the asaq winthrop experience |
publisher |
BMC |
publishDate |
2011 |
url |
https://doi.org/10.1186/1475-2875-10-143 https://doaj.org/article/8a22bf2c781c46a7b5649a589de37dad |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Malaria Journal, Vol 10, Iss 1, p 143 (2011) |
op_relation |
http://www.malariajournal.com/content/10/1/143 https://doaj.org/toc/1475-2875 doi:10.1186/1475-2875-10-143 1475-2875 https://doaj.org/article/8a22bf2c781c46a7b5649a589de37dad |
op_doi |
https://doi.org/10.1186/1475-2875-10-143 |
container_title |
Malaria Journal |
container_volume |
10 |
container_issue |
1 |
_version_ |
1766348205159612416 |